{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:54:18Z","timestamp":1794254058451,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12325-021-01838-z","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T21:02:30Z","timestamp":1627074150000},"page":"4659-4674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Access to Chimeric Antigen Receptor T\u00a0Cell Therapy for Diffuse Large B\u00a0Cell Lymphoma"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2684-2962","authenticated-orcid":false,"given":"Sophie","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika P.","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"11","key":"1838_CR1","doi-asserted-by":"publisher","first-page":"e013059","DOI":"10.1136\/bmjopen-2016-013059","volume":"6","author":"C Kelly","year":"2016","unstructured":"Kelly C, Hulme C, Farragher T, Clarke G. Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review. BMJ Open. 2016;6(11):e013059. https:\/\/doi.org\/10.1136\/bmjopen-2016-013059.","journal-title":"BMJ Open"},{"issue":"2","key":"1838_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1748-0361.2012.00445.x","volume":"29","author":"D Su","year":"2013","unstructured":"Su D, Pratt W, Salinas J, Wong R, Pagan JA. Rural-urban differences in health services utilization in the US-Mexico border region. J Rural Health. 2013;29(2):215\u201323. https:\/\/doi.org\/10.1111\/j.1748-0361.2012.00445.x.","journal-title":"J Rural Health"},{"issue":"4 suppl 1","key":"1838_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/MLR.0000000000000296","volume":"53","author":"SA Friedman","year":"2015","unstructured":"Friedman SA, Frayne SM, Berg E, et al. Travel time and attrition from VHA care among women veterans: how far is too far? Med Care. 2015;53(4 suppl 1):S15\u201322. https:\/\/doi.org\/10.1097\/MLR.0000000000000296.","journal-title":"Med Care"},{"key":"1838_CR4","first-page":"1","volume-title":"International encyclopedia of geography: people, the earth, environment and technology","author":"LSC Pun-Cheng","year":"2016","unstructured":"Pun-Cheng LSC. Distance decay. In: Richardson D, Castree N, Goodchild MF, Kobayashi A, Liu W, Marston RA, editors. International encyclopedia of geography: people, the earth, environment and technology. Hoboken: Wiley; 2016. p. 1\u20135."},{"issue":"11","key":"1838_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","volume":"24","author":"A Chari","year":"2019","unstructured":"Chari A, Romanus D, DasMahapatra P, et al. Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM). Oncologist. 2019;24(11):1479\u201387. https:\/\/doi.org\/10.1634\/theoncologist.2018-0724.","journal-title":"Oncologist"},{"issue":"9","key":"1838_CR6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1634\/theoncologist.2011-0384","volume":"17","author":"SH Javid","year":"2012","unstructured":"Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012;17(9):1180\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2011-0384.","journal-title":"Oncologist"},{"issue":"4","key":"1838_CR7","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1200\/jop.2016.017327","volume":"13","author":"M Patel","year":"2017","unstructured":"Patel M, Periyakoil V, Douglas W, et al. Redesigning cancer care delivery: views from patients and caregivers. J Oncol Pract. 2017;13(4):e291\u2013302. https:\/\/doi.org\/10.1200\/jop.2016.017327.","journal-title":"J Oncol Pract"},{"issue":"1","key":"1838_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"26","key":"1838_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1838_CR10","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH risk evaluation and mitigation strategy. 2019. https:\/\/www.kymriah-rems.com\/. Accessed 10 Sep 2019."},{"key":"1838_CR11","unstructured":"Kite Pharma. YESCARTA risk evaluation and mitigation strategy (REMS). 2020 https:\/\/www.yescartarems.com\/. Accessed 10 Sep 2019."},{"key":"1838_CR12","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel) prescribing information. 2018. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf. Accessed 9 Mar 2019."},{"key":"1838_CR13","unstructured":"Kite Pharma. YESCARTA (axicabtagene ciloleucel) prescribing information. 2019. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf. Accessed 9 Mar 2019."},{"key":"1838_CR14","unstructured":"Mayo Clinic. CAR-T cell therapy program - frequently asked questions. 2019. https:\/\/www.mayoclinic.org\/departments-centers\/car-t-cell-therapy-program\/sections\/gnc-20405547. Accessed 16 Dec 2019."},{"issue":"1","key":"1838_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.32614\/RJ-2013-014","volume":"5","author":"D Kahle","year":"2013","unstructured":"Kahle D, Wickham H. ggmap: spatial visualization with ggplot2. R J. 2013;5(1):144\u201361.","journal-title":"R J"},{"key":"1838_CR16","unstructured":"Centers for Medicare & Medicaid Services. Glossary and acronyms. 2016. https:\/\/www.cms.gov\/OpenPayments\/About\/Glossary-and-Acronyms.html#teachinghospital. Accessed 12 Aug 2019."},{"key":"1838_CR17","unstructured":"Centers for Medicare & Medicaid Services. 2019 reporting cycle: teaching hospital list. 2018. https:\/\/www.cms.gov\/OpenPayments\/Downloads\/2019-Reporting-Cycle-Teaching-Hospital-List-pdf.pdf. Accessed 31 July 2019."},{"key":"1838_CR18","unstructured":"Kite Pharma. Where can YESCARTA be received? 2019. https:\/\/www.yescarta.com\/treatment-centers. Accessed 31 Jan 2020."},{"key":"1838_CR19","unstructured":"Novartis Pharmaceuticals Corporation. Find a KYMRIAH treatment center. 2020. https:\/\/www.us.kymriah.com\/treatment-center-locator\/. Accessed 12 July 2021."},{"key":"1838_CR20","unstructured":"American Hospital Association. Fast facts on US hospitals. 2019. https:\/\/www.aha.org\/statistics\/fast-facts-us-hospitals. Accessed 12 Aug 2019."},{"key":"1838_CR21","unstructured":"National Cancer Institute. Find a cancer center. 2020. https:\/\/www.cancer.gov\/research\/nci-role\/cancer-centers\/find. Accessed 31 Jan 2020."},{"key":"1838_CR22","unstructured":"Centers for Medicare & Medicaid Services. Oncology care model practice list. 2020. https:\/\/innovation.cms.gov\/initiatives\/Oncology-Care\/. Accessed 31 Jan 2020."},{"key":"1838_CR23","unstructured":"Association of Community Cancer Centers. Find a cancer program. 2020. https:\/\/www.accc-cancer.org\/. Accessed 31 Jan 2020."},{"issue":"9","key":"1838_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790\u20135.","journal-title":"Am J Hematol"},{"issue":"27","key":"1838_CR25","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1838_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","volume":"94","author":"J Rovira","year":"2015","unstructured":"Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803\u201312. https:\/\/doi.org\/10.1007\/s00277-014-2271-1.","journal-title":"Ann Hematol"},{"issue":"2","key":"1838_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216\u201321. https:\/\/doi.org\/10.1038\/bmt.2016.213.","journal-title":"Bone Marrow Transplant"},{"key":"1838_CR28","unstructured":"US Census Bureau. Geographies. 2019. https:\/\/www.census.gov\/geographies\/reference-files\/time-series\/geo\/centers-population.html. Accessed 11 Sep 2019."},{"key":"1838_CR29","unstructured":"Centers for Medicare & Medicaid Services. Rural-urban disparities in health care in medicare. 2018. https:\/\/www.cms.gov\/About-CMS\/Agency-Information\/OMH\/Downloads\/Rural-Urban-Disparities-in-Health-Care-in-Medicare-Report.pdf. Accessed July 31 2019."},{"key":"1838_CR30","unstructured":"National Bureau of Economic Research. CMS's SSA to FIPS CBSA and MSA county crosswalk (2017). https:\/\/www.nber.org\/research\/data\/ssa-federal-information-processing-series-fips-core-based-statistical-area-cbsa-and-metropolitan-and. Accessed May 28 2019."},{"issue":"9","key":"1838_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2013.52.3845","volume":"32","author":"NN Massarweh","year":"2014","unstructured":"Massarweh NN, Chiang YJ, Xing Y, et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol. 2014;32(9):942\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.52.3845.","journal-title":"J Clin Oncol"},{"key":"1838_CR32","doi-asserted-by":"publisher","unstructured":"Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D. Geographic access to cancer care in the U.S. Cancer. 2008;112(4):909\u201318. https:\/\/doi.org\/10.1002\/cncr.23229.","DOI":"10.1002\/cncr.23229"},{"issue":"5","key":"1838_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ijrobp.2014.06.038","volume":"90","author":"EH Wang","year":"2014","unstructured":"Wang EH, Mougalian SS, Soulos PR, et al. Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: a National Cancer Data Base analysis. Int J Radiat Oncol Biol Phys. 2014;90(5):993\u20131000. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.06.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1838_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-011-1549-4","volume":"129","author":"T Onega","year":"2011","unstructured":"Onega T, Cook A, Kirlin B, et al. The influence of travel time on breast cancer characteristics, receipt of primary therapy, and surveillance mammography. Breast Cancer Res Treat. 2011;129(1):269\u201375. https:\/\/doi.org\/10.1007\/s10549-011-1549-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1838_CR35","unstructured":"University of Iowa Hospitals and Clinics. CAR T-cell therapy. 2019. https:\/\/uihc.org\/health-topics\/car-t-cell-therapy. Accessed 28 May 2019."},{"key":"1838_CR36","unstructured":"Centers for Disease Control and Prevention. Cancer clusters. 2019. https:\/\/www.cdc.gov\/nceh\/clusters\/default.htm. Accessed 28 May 2019."},{"key":"1838_CR37","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975\u20132016) <Katrina\/Rita Population Adjustment>. 2019. www.seer.cancer.gov. Accessed 28 May 2019."},{"issue":"suppl 1","key":"1838_CR38","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2019-127566","volume":"134","author":"CR Bachier","year":"2019","unstructured":"Bachier CR, Palomba ML, Abramson JS, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (R\/R) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: TRANSCEND NHL 001, Outreach, and PILOT. Blood. 2019;134(suppl 1):2868. https:\/\/doi.org\/10.1182\/blood-2019-127566.","journal-title":"Blood"},{"issue":"4","key":"1838_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL.\u201d Nat Rev Clin Oncol. 2018;15(4):218. https:\/\/doi.org\/10.1038\/nrclinonc.2018.19.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1838_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.25270\/jcp.2018.10.00039","volume":"4","author":"S Smith","year":"2018","unstructured":"Smith S, Essell J. Evolving the delivery of CAR T-cell therapies to the outpatient setting. J Clin Pathw. 2018;4(8):42\u20137. https:\/\/doi.org\/10.25270\/jcp.2018.10.00039.","journal-title":"J Clin Pathw"},{"issue":"4","key":"1838_CR41","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1748-0361.2008.00186.x","volume":"24","author":"LM Baldwin","year":"2008","unstructured":"Baldwin LM, Cai Y, Larson EH, et al. Access to cancer services for rural colorectal cancer patients. J Rural Health. 2008;24(4):390\u20139. https:\/\/doi.org\/10.1111\/j.1748-0361.2008.00186.x.","journal-title":"J Rural Health"},{"issue":"17","key":"1838_CR42","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/cncr.30727","volume":"123","author":"T Onega","year":"2017","unstructured":"Onega T, Alford-Teaster J, Wang F. Population-based geographic access to parent and satellite National Cancer Institute Cancer Center Facilities. Cancer. 2017;123(17):3305\u201311. https:\/\/doi.org\/10.1002\/cncr.30727.","journal-title":"Cancer"},{"issue":"17","key":"1838_CR43","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/cncr.30744","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein MW, Loppenberg B, Karabon P, et al. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer. 2017;123(17):3241\u201352. https:\/\/doi.org\/10.1002\/cncr.30744.","journal-title":"Cancer"},{"issue":"12","key":"1838_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10916-017-0850-0","volume":"41","author":"Y Xu","year":"2017","unstructured":"Xu Y, Fu C, Onega T, Shi X, Wang F. Disparities in geographic accessibility of National Cancer Institute Cancer Centers in the United States. J Med Syst. 2017;41(12):203. https:\/\/doi.org\/10.1007\/s10916-017-0850-0.","journal-title":"J Med Syst"},{"issue":"15","key":"1838_CR45","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1002\/cncr.31571","volume":"124","author":"EM Graboyes","year":"2018","unstructured":"Graboyes EM, Ellis MA, Li H, Kaczmar JM, et al. Racial and ethnic disparities in travel for head and neck cancer treatment and the impact of travel distance on survival. Cancer. 2018;124(15):3181\u201391. https:\/\/doi.org\/10.1002\/cncr.31571.","journal-title":"Cancer"},{"issue":"2","key":"1838_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1748-0361.2006.00022.x","volume":"22","author":"L Chan","year":"2006","unstructured":"Chan L, Hart LG, Goodman DC. Geographic access to health care for rural Medicare beneficiaries. J Rural Health. 2006;22(2):140\u20136. https:\/\/doi.org\/10.1111\/j.1748-0361.2006.00022.x.","journal-title":"J Rural Health"},{"issue":"6 pt 1","key":"1838_CR47","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1111\/j.1475-6773.2004.00324.x","volume":"39","author":"WT Tai","year":"2004","unstructured":"Tai WT, Porell FW, Adams EK. Hospital choice of rural Medicare beneficiaries: patient, hospital attributes, and the patient-physician relationship. Health Serv Res. 2004;39(6 pt 1):1903\u201322. https:\/\/doi.org\/10.1111\/j.1475-6773.2004.00324.x.","journal-title":"Health Serv Res"},{"issue":"6","key":"1838_CR48","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","volume":"24","author":"K Perica","year":"2018","unstructured":"Perica K, Curran KJ, Brentjens RJ, Giralt SA. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135\u201341. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.018.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1838_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1188\/19.CJON.S1.20-26","volume":"23","author":"L Taylor","year":"2019","unstructured":"Taylor L, Rodriguez ES, Reese A, Anderson K. Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy. Clin J Oncol Nurs. 2019;23(2):20\u20136. https:\/\/doi.org\/10.1188\/19.CJON.S1.20-26.","journal-title":"Clin J Oncol Nurs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01838-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01838-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:27:12Z","timestamp":1630438032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01838-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01838-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}